J. Thomas Dietz's Insider Trades & SAST Disclosures
J. Thomas Dietz's most recent trade in Leap Therapeutics Inc was a trade of 30,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Oct. 2, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern J. Thomas Dietz.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Leap Therapeutics Inc | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | J. Thomas Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Eiger BioPharmaceuticals Inc | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Paratek Pharmaceuticals Inc. | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 20,000 | 70,000 (0%) | 0% | 0 | Common Stock | |
| Eiger BioPharmaceuticals Inc | Thomas J. Dietz | Director | Purchase of securities on an exchange or from another person at price $ 1.43 per share. | 23 Jan 2023 | 50,000 | 50,000 (0%) | 0% | 1.4 | 71,580 | Common Stock |
| Eiger BioPharmaceuticals Inc | Thomas J. Dietz | Director | Sale of securities on an exchange or to another person at price $ 1.17 per share. | 22 Dec 2022 | 22,500 | 21,000 (0%) | 0% | 1.2 | 26,303 | Common Stock |
| Paratek Pharmaceuticals Inc. | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 20,000 | 50,000 (0%) | 0% | 0 | Common Stock | |
| Leap Therapeutics Inc | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Eiger BioPharmaceuticals Inc | Thomas J. Dietz | Director | Purchase of securities on an exchange or from another person at price $ 8.48 per share. | 09 Apr 2021 | 1,500 | 36,500 (0%) | 0% | 8.5 | 12,720 | Common Stock |
| Eiger BioPharmaceuticals Inc | Thomas J. Dietz | Director | Purchase of securities on an exchange or from another person at price $ 8.50 per share. | 09 Apr 2021 | 1,000 | 37,500 (0%) | 0% | 8.5 | 8,500 | Common Stock |
| Eiger BioPharmaceuticals Inc | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Eiger BioPharmaceuticals Inc | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2021 | 5,000 | 35,000 (0%) | 0% | 0 | Common Stock | |
| Paratek Pharmaceuticals Inc. | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 9,000 | 30,000 (0%) | 0% | 0 | Common Stock | |
| Paratek Pharmaceuticals Inc. | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 7,000 | 7,000 | - | - | Stock Option (right to buy) | |
| Leap Therapeutics Inc | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 37,300 | 37,300 | - | - | Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2020 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Apr 2020 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges